Glycotope (Germany)

Recent papers from Glycotope (Germany)

1. Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical modelsCancer Immunology Research · 2026
2. Abstract 5896: Platform approach to develop antibodies specifically recognizing cancer-associated glycoformsCancer Research · 2024
3. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution StudiesInternational Journal of Molecular Sciences · 2024
4. Targeting a cancer-specific LYPD3 glycoform for tumor therapyFrontiers in Drug Discovery · 2023
5. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumorsFrontiers in Immunology · 2023
6. Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free SystemsInternational Journal of Molecular Sciences · 2022
7. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsESMO Open · 2022
8. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyESMO Open · 2021
9. A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX studyESMO Open · 2021
10. Structure and activity of human surfactant protein D from different natural sourcesAJP Lung Cellular and Molecular Physiology · 2020
11. Fully human glyco-optimized recombinant FSH (follitropin epsilon) – a randomized, comparator-controlled phase II clinical trialReproductive BioMedicine Online · 2019
12. A novel scale‐down mimic of perfusion cell culture using sedimentation in an automated microbioreactor (SAM)Biotechnology Progress · 2019
13. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated CounterpartsFrontiers in Immunology · 2018
14. Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumoursESMO Open · 2018
15. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomasESMO Open · 2018
16. Targeting G Protein‐Coupled Receptors by Capture Compound Mass Spectrometry: A Case Study with SertindoleChemBioChem · 2017
17. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trialsHuman Reproduction · 2017
18. Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer ImmunotherapyBioengineering · 2017
19. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 PolymorphismCancer Research · 2016
20. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomasEuropean Journal of Cancer · 2016